ArticleProceedings of the National Academy of Sciences of the United States of America2017
Single-cell analysis resolves the cell state transition and signaling dynamics associated with melanoma drug-induced resistance.
Abstract read
In one paragraph
Article in Proceedings of the National Academy of Sciences of the United States of America, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 143 papers.
0numbers the graph read from it
0cells of the map it votes in
143citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
143 citing papers in PubMed.
- A single-cell lens into the co-evolution of genotypes and phenotypes in cancer.Nature reviews. Cancer · 2026Review
- Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multiselective Inhibitors in NRAS-Mutated Melanoma.Cancer research · 2026Article
- Sequential transcriptional waves and NF-κB-driven chromatin remodeling direct drug-induced dedifferentiation in cancer.Nature communications · 2026Article
- miRNA-driven cancer cell plasticity, tolerance and therapy resistance: lessons from melanoma.Molecular cancer · 2026Review
- Genomic innovations in cancer prevention, diagnosis, prognosis and precision therapeutics.Frontiers in genetics · 2026Review
- Editorial: Multiomics advances: bridging gaps in understanding intricate biological systems.Frontiers in plant science · 2026Article
- Cell State Transitions Drive the Evolution of Disease Progression in B-Lymphoblastic Leukemia.Cancer research communications · 2026Article
- Proteomics in Antitumor Drug Target Discovery, Toxicity, Resistance, and Precision Oncology.Drug design, development and therapy · 2026Review
- A Systematic Review of Evidence for the Cost of Therapeutic Resistance in Cancer.bioRxiv : the preprint server for biology · 2025Article
- A BRN2:MYC transcriptional axis regulates interconversion between therapy-resistant and tumorigenic phenotypes in melanoma.Cell reports · 2025Article
- SOX9 drives a stem-like transcriptional state and platinum resistance in high-grade serous ovarian cancer.The Journal of clinical investigation · 2025Article
- A TGF-βR/IL-2R immunomodulatory fusion protein transforms immunosuppression into T cell activation to enhance adoptive T cell therapy.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Optimal dosing of anti-cancer treatment under drug-induced plasticity.NPJ systems biology and applications · 2025Article
- A statistical framework for detecting therapy-induced resistance from drug screens.NPJ systems biology and applications · 2025Article
- Enhanced bioluminescence imaging of tumor cells surviving chemotherapy in a murine model of triple-negative breast cancer.NPJ breast cancer · 2025Article
- Unlocking Cellular Memory and Gene Regulatory Networks: Pioneering the Future of Therapeutic Innovations.Cells · 2025Article
- Signaling and transcriptional dynamics underlying early adaptation to oncogenic BRAF inhibition.Cell systems · 2025Article
- The end of the genetic paradigm of cancer.PLoS biology · 2025Review
- Mannose metabolism reshapes T cell differentiation to enhance anti-tumor immunity.Cancer cell · 2025Article
- Transformer-based modeling of Clonal Selection and Expression Dynamics reveals resistance mechanisms in breast cancer.NPJ systems biology and applications · 2025Article
83 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Yapeng SuNanoSystems Biology Cancer Center, California Institute of Technology, Pasadena, CA 91125.
Wei WeiNanoSystems Biology Cancer Center, California Institute of Technology, Pasadena, CA 91125; weiwei@mednet.ucla.edu aribas@mednet.ucla.edu heath@caltech.edu.ORCID 0000-0002-1018-7708
Lidia RobertDepartment of Medicine, University of California, Los Angeles, CA 90095.
Min XueNanoSystems Biology Cancer Center, California Institute of Technology, Pasadena, CA 91125.
Jennifer TsoiDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA 90095.
Angel Garcia-DiazDepartment of Medicine, University of California, Los Angeles, CA 90095.
Blanca Homet MorenoDepartment of Medicine, University of California, Los Angeles, CA 90095.
Jungwoo KimNanoSystems Biology Cancer Center, California Institute of Technology, Pasadena, CA 91125.ORCID 0000-0002-5215-2044
Rachel H NgNanoSystems Biology Cancer Center, California Institute of Technology, Pasadena, CA 91125.
Jihoon W LeeNanoSystems Biology Cancer Center, California Institute of Technology, Pasadena, CA 91125.ORCID 0000-0002-6749-5111
Richard C KoyaDepartment of Surgery, Division of Surgical-Oncology, University of California, Los Angeles, CA 90095.
Begonya Comin-AnduixJonsson Comprehensive Cancer Center, University of California, Los Angeles, CA 90095.
Thomas G GraeberDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA 90095.ORCID 0000-0001-8574-9181
Antoni RibasDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA 90095; weiwei@mednet.ucla.edu aribas@mednet.ucla.edu heath@caltech.edu.
James R HeathNanoSystems Biology Cancer Center, California Institute of Technology, Pasadena, CA 91125; weiwei@mednet.ucla.edu aribas@mednet.ucla.edu heath@caltech.edu.
Funding
Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI JOHN A GLASPY · 1985 to 2026
$134.5MUCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0MRepurposing of cancer therapeutics for treatment of patients with COVID-19 diseaseU54CA199090 · NCI · INSTITUTE FOR SYSTEMS BIOLOGY · PI HEATH, JAMES R., RIBAS, ANTONI · 2015 to 2020
$11.4MNext Generation Cancer Immunotherapies to Defeat MelanomaR35CA197633 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ANTONI RIBAS · 2015 to 2026
$10.4MUCLA Tumor Immunology Training ProgramT32CA009120 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Steven M. Dubinett, MICHAEL A TEITELL · 1985 to 2026
$10.3MTARGETED COMBINATORIAL TREATMENT OF BRAF MELANOMASP01CA168585 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI RIBAS, ANTONI · 2013 to 2017
$8.4MNCATS NIH HHS UL1 TR000124NCI NIH HHS P01 CA168585NCI NIH HHS P30 CA016042NCI NIH HHS R35 CA197633NCI NIH HHS T32 CA009120NCI NIH HHS U54 CA199090
Abstract
Continuous BRAF inhibition of
Indexed as
Drug Resistance, NeoplasmSignal TransductionSingle-Cell AnalysisAdaptation, PhysiologicalAntineoplastic AgentsCell Line, TumorGene Expression ProfilingHumansMAP Kinase Signaling SystemMarkov ChainsMelanomaNF-kappa BPhenotypeProteomeProteomicsProto-Oncogene Proteins B-rafAntineoplastic AgentsNF-kappa BProteomeProto-Oncogene Proteins B-rafadaptive resistancecell state transitionMarkov chain modelmelanomasingle-cell analysis
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.